Background. 29 GPA patients from the Northern Norway vasculitis disease registry received rituximab (RTX) induction and maintenance. 24% and 31% had, respectively, severe and chronic infections while 45% had hypogammaglobulinemia and 28% discontinued RTX due to hypogammaglobulinemia. The aim of the study was to examine how known predictors and adverse events interacted with adverse events using structural statistical methods. Methods. Five predictors (age, cyclophosphamide, total Ig and CD4/CD8 ratio prior RTX, and type of RTX maintenance regimen) and 4 adverse events (severe and chronic infections, hypogammaglobulinemia, and RTX discontinuation) were modeled in principal component and redundancy analyses. Results. The 5 predictors explaine...
BACKGROUND: Rituximab (RTX; anti-CD20 mAb) is a treatment option in children with refractory immune ...
Background: Rituximab (RTX) is an anti-CD20 chimeric monoclonal antibody recommended as off- label t...
BACKGROUND: Rituximab (RTX; anti-CD20 mAb) is a treatment option in children with refractory immune ...
Objective: To evaluate predictors of serious infection events (SIEs) during rituximab (RTX) therapy ...
Rituximab (RTX) is a monoclonal antibody against CD20, commonly used in the treatment of hematologic...
OBJECTIVES: Rituximab has become the cornerstone of induction treatment in ANCA-associated vasculiti...
Rituximab (RTX) is an anti-CD20 antibody used successfully in granulomatosis with polyangiitis (GPA)...
International audienceBackground and Objectives To determine the frequency of hypogammaglobulinemia ...
Objectives: To assess efficacy and safety of rituximab (RTX) induction and maintenance therapy for g...
The burden of hypogammaglobulinaemia following rituximab (RTX) treatment in rheumatic diseases has n...
Objective. Chronic nasal carriage of Staphylococcus aureus (SA) increases the risk of relapse while ...
Importance: Rituximab is an anti-CD20 chimeric antibody used in a wide variety of clinical indicatio...
Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with p...
Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. H...
Objective: To evaluate the characteristics of patients with autoimmune disease with hypogammaglobuli...
BACKGROUND: Rituximab (RTX; anti-CD20 mAb) is a treatment option in children with refractory immune ...
Background: Rituximab (RTX) is an anti-CD20 chimeric monoclonal antibody recommended as off- label t...
BACKGROUND: Rituximab (RTX; anti-CD20 mAb) is a treatment option in children with refractory immune ...
Objective: To evaluate predictors of serious infection events (SIEs) during rituximab (RTX) therapy ...
Rituximab (RTX) is a monoclonal antibody against CD20, commonly used in the treatment of hematologic...
OBJECTIVES: Rituximab has become the cornerstone of induction treatment in ANCA-associated vasculiti...
Rituximab (RTX) is an anti-CD20 antibody used successfully in granulomatosis with polyangiitis (GPA)...
International audienceBackground and Objectives To determine the frequency of hypogammaglobulinemia ...
Objectives: To assess efficacy and safety of rituximab (RTX) induction and maintenance therapy for g...
The burden of hypogammaglobulinaemia following rituximab (RTX) treatment in rheumatic diseases has n...
Objective. Chronic nasal carriage of Staphylococcus aureus (SA) increases the risk of relapse while ...
Importance: Rituximab is an anti-CD20 chimeric antibody used in a wide variety of clinical indicatio...
Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with p...
Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. H...
Objective: To evaluate the characteristics of patients with autoimmune disease with hypogammaglobuli...
BACKGROUND: Rituximab (RTX; anti-CD20 mAb) is a treatment option in children with refractory immune ...
Background: Rituximab (RTX) is an anti-CD20 chimeric monoclonal antibody recommended as off- label t...
BACKGROUND: Rituximab (RTX; anti-CD20 mAb) is a treatment option in children with refractory immune ...